AU2019259112B2 - Compounds having a tubulin-polymerisation-inhibiting activity and immunomodulatory properties - Google Patents

Compounds having a tubulin-polymerisation-inhibiting activity and immunomodulatory properties Download PDF

Info

Publication number
AU2019259112B2
AU2019259112B2 AU2019259112A AU2019259112A AU2019259112B2 AU 2019259112 B2 AU2019259112 B2 AU 2019259112B2 AU 2019259112 A AU2019259112 A AU 2019259112A AU 2019259112 A AU2019259112 A AU 2019259112A AU 2019259112 B2 AU2019259112 B2 AU 2019259112B2
Authority
AU
Australia
Prior art keywords
group
alkyl group
hydrogen atom
compound
representing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019259112A
Other languages
English (en)
Other versions
AU2019259112A1 (en
Inventor
Mouad Alami
Sébastien APCHER
Romain DARRIGRAND
Abdallah Hamze
Ilhem KHELIFI
Timothée NARET
Olivier Provot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay filed Critical Centre National de la Recherche Scientifique
Publication of AU2019259112A1 publication Critical patent/AU2019259112A1/en
Application granted granted Critical
Publication of AU2019259112B2 publication Critical patent/AU2019259112B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
AU2019259112A 2018-04-27 2019-04-26 Compounds having a tubulin-polymerisation-inhibiting activity and immunomodulatory properties Active AU2019259112B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1853709A FR3080620B1 (fr) 2018-04-27 2018-04-27 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
FR1853709 2018-04-27
PCT/FR2019/050982 WO2019207257A1 (fr) 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Publications (2)

Publication Number Publication Date
AU2019259112A1 AU2019259112A1 (en) 2020-11-26
AU2019259112B2 true AU2019259112B2 (en) 2024-02-08

Family

ID=63036097

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019259112A Active AU2019259112B2 (en) 2018-04-27 2019-04-26 Compounds having a tubulin-polymerisation-inhibiting activity and immunomodulatory properties

Country Status (9)

Country Link
US (2) US11634405B2 (enExample)
EP (1) EP3784662B1 (enExample)
JP (1) JP7408894B2 (enExample)
AU (1) AU2019259112B2 (enExample)
CA (1) CA3097622A1 (enExample)
DK (1) DK3784662T3 (enExample)
ES (1) ES2932370T3 (enExample)
FR (1) FR3080620B1 (enExample)
WO (1) WO2019207257A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN115417860B (zh) * 2020-08-03 2023-10-20 中国药科大学 一种具有抗肿瘤活性的喹唑啉类衍生物及其合成方法和用途
CN113173915B (zh) * 2021-03-29 2022-12-09 中南大学湘雅医院 抗皮肤肿瘤化合物及其应用
CN113620874B (zh) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CA2545340A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
AP2006003619A0 (en) * 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
AU2006204052A1 (en) 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
GB0508717D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007034143A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab Quinazoline derivatives as anticancer agents
FR2914640B1 (fr) 2007-04-04 2012-11-16 Centre Nat Rech Scient Iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de polymerisation de la tubuline

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MAHAL K. ET AL.: CHEMMEDCHEM, vol. 9, no. 4, 1 January 2014 (2014-01-01), pages 847 - 854, XP002784057 *

Also Published As

Publication number Publication date
US11634405B2 (en) 2023-04-25
US20230203005A1 (en) 2023-06-29
JP2021522244A (ja) 2021-08-30
WO2019207257A1 (fr) 2019-10-31
AU2019259112A1 (en) 2020-11-26
WO2019207257A8 (fr) 2019-11-21
EP3784662A1 (fr) 2021-03-03
ES2932370T3 (es) 2023-01-18
FR3080620A1 (fr) 2019-11-01
FR3080620B1 (fr) 2021-11-12
US12371417B2 (en) 2025-07-29
EP3784662B1 (fr) 2022-11-09
US20210230140A1 (en) 2021-07-29
DK3784662T3 (da) 2022-12-19
CA3097622A1 (fr) 2019-10-31
JP7408894B2 (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
US12371417B2 (en) Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties
CA3030510C (en) Azole dione compounds with anti-cancer activity
EP4107146A1 (en) Gcn2 modulator compounds
CA3125058A1 (en) Fak inhibitor and drug combination thereof
CN106866571B (zh) 杂环脲类化合物及其药物组合物和应用
JP7181565B2 (ja) Ｙａｐ－ｔｅａｄ結合を阻害する化合物、およびそれを有効成分として含有する癌の予防または治療用医薬組成物
JP6291066B2 (ja) ナフチル尿素誘導体およびその医療適用
CA3090485C (en) Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
CN106995437A (zh) 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途
CN102241674A (zh) 1,1-二甲基-β-咔啉-3-甲酰基氨基酸苄酯的合成和抗肿瘤活性评价
AU2017258304A1 (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases
CN1807413B (zh) 咔唑磺酰胺衍生物及其制备方法
CN106243047B (zh) 具有VEGFR-2和B-raf双重抑制作用的喹喔啉酮双芳基脲及其衍生物、制备方法及其应用
CN103002899A (zh) 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物
JP2016522223A (ja) チロシンキナーゼ阻害活性を有する物質ならびにその調製方法および使用
JP2021518855A (ja) Ｗｎｔシグナル伝達経路阻害剤としてのピラゾール誘導体
WO2014150252A1 (en) Methods of treatment associated with the granulocyte colony-stimulating factor receptor
RU2605091C2 (ru) 2-амино-1-арил-5-(3,3-диметил-2-оксобутилиден)-4-оксо-n-(тиазол-5-ил)-4,5-дигидро-1н-пиррол-3-карбоксамиды, проявляющие противоопухолевую и антирадикальную активность, способ их получения и фармацевтическая композиция на их основе
CN108187055B (zh) 一种具有协同增效作用的抗癌组合物
CN111320557B (zh) 缩氨基脲类化合物及其用途
HK40029801A (en) Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
KR20230159174A (ko) Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물
WO2019134082A1 (en) Novel pyrimidine derivatives as mth1 inhibitors
CN108186630A (zh) 靛红类似物在制备抗肿瘤药物中的应用
CN105017227A (zh) N-(1h-吡唑-5-基)喹唑啉-4-胺类化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)